Gliclazide is a second-generation sulfonylurea derivative used in the treatment of T2DM that exerts its effects by selectively binding to the sulfonylurea receptor 1 (SUR1) on the membrane of pancreatic β-cells, triggering the exocytosis of insulin granules upon the activation (Singh and Singh, 2016). Here, ABCC8 is linked to type 2 diabetes mellitus.